Clinical Trials Browser

Interventional × obinutuzumab × Tumor-Agnostic × Clear all

NCT03113695 2022-07-05

Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome

Phase 1 Completed

Neoplasms